Literature DB >> 9701408

The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics.

J Van Schoor1, G F Joos, B L Chasson, R J Brouard, R A Pauwels.   

Abstract

Inhalation of neurokinin (NK) A causes bronchoconstriction in patients with asthma. The NKA-induced bronchoconstriction in isolated human airways is mediated via the NK2 receptor and inhibited by SR 48968, a potent and specific nonpeptide tachykinin NK2 receptor antagonist. In the present study, the effect of orally administered SR 48968 on NKA-induced bronchoconstriction was examined in 12 mild asthmatics. On the screening day and during the study periods, increasing concentrations of NKA (3.3 x 10(-9) to 1.0 x 10(-6) mol x mL(-1)) were inhaled, until the forced expiratory volume in one second (FEV1) and specific airway conductance (sGaw) decreased by at least 20 and 50%, respectively. During the study periods, 100 mg SR 48968 or matched placebo was ingested in a double-blind, randomized, crossover fashion and NKA provocation was performed at 1.5 and 24 h after dosing. At 1.5 h, the mean (SEM) log10 provocative concentration of NKA causing a 20% fall in FEV1 (PC20 FEV1) was -6.25 (0.20) after SR 48968 and -6.75 (0.17) after placebo (p=0.05); the mean log10 provocative concentration of NKA causing a 35% fall in sGaw (PC35 sGaw) was -7.02 (0.28) after SR 48968 and -7.64 (0.19) after placebo (p=0.05). At 24 h, the mean log10 PC20 FEV1 was -6.21 (0.17) after SR 48968 and -6.65 (0.11) after placebo (p=0.05); the mean log10 PC35 sGaw was -6.85 (0.23) after SR 48968 and -7.17 (0.15) after placebo (nonsignificant). As PC20 FEV1 and/or PC35 sGaw were not reached in up to 4 patients per SR 48968 group, the differences between SR 48968 and placebo were underestimated. In conclusion, oral treatment with 100 mg SR 48968 caused a significant inhibition of neurokinin A-induced bronchoconstriction in asthmatics. This finding constitutes the first evidence of inhibition of sensory neuropeptide-induced bronchoconstriction by a selective tachykinin receptor antagonist in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701408     DOI: 10.1183/09031936.98.12010017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  10 in total

Review 1.  Asthma--the changing face of drug therapy.

Authors:  J Legg; J Warner
Journal:  Indian J Pediatr       Date:  2000-02       Impact factor: 1.967

Review 2.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

3.  Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs.

Authors:  F L Ricciardolo; M Trevisani; P Geppetti; J A Nadel; S Amadesi; C Bertrand
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 4.  The role of neuroeffector mechanisms in the pathogenesis of asthma.

Authors:  G F Joos
Journal:  Curr Allergy Asthma Rep       Date:  2001-03       Impact factor: 4.806

Review 5.  TRP channels and traffic-related environmental pollution-induced pulmonary disease.

Authors:  Armen N Akopian; E Robert Fanick; Edward G Brooks
Journal:  Semin Immunopathol       Date:  2016-02-02       Impact factor: 9.623

6.  Disodium cromoglycate inhibits capsaicin-induced eosinophil infiltration of conjunctiva independent of mast cells.

Authors:  Nobuyuki Ebihara; Motoaki Nishikawa; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2006 May-Jun       Impact factor: 2.211

7.  Neurokinin-1 receptor antagonist treatment in polymicrobial sepsis: molecular insights.

Authors:  Akhil Hegde; Yung-Hua Koh; Shabbir M Moochhala; Madhav Bhatia
Journal:  Int J Inflam       Date:  2010-09-20

Review 8.  Tachykinin receptors antagonism for asthma: a systematic review.

Authors:  Renata Ramalho; Raquel Soares; Nuno Couto; André Moreira
Journal:  BMC Pulm Med       Date:  2011-08-02       Impact factor: 3.317

9.  A TRPA1 inhibitor suppresses neurogenic inflammation and airway contraction for asthma treatment.

Authors:  Alessia Balestrini; Victory Joseph; Michelle Dourado; Rebecca M Reese; Shannon D Shields; Lionel Rougé; Daniel D Bravo; Tania Chernov-Rogan; Cary D Austin; Huifen Chen; Lan Wang; Elisia Villemure; Daniel G M Shore; Vishal A Verma; Baihua Hu; Yong Chen; Laurie Leong; Chris Bjornson; Kathy Hötzel; Alvin Gogineni; Wyne P Lee; Eric Suto; Xiumin Wu; John Liu; Juan Zhang; Vineela Gandham; Jianyong Wang; Jian Payandeh; Claudio Ciferri; Alberto Estevez; Christopher P Arthur; Jens Kortmann; Ryan L Wong; Jose E Heredia; Jonas Doerr; Min Jung; Jason A Vander Heiden; Merone Roose-Girma; Lucinda Tam; Kai H Barck; Richard A D Carano; Han Ting Ding; Bobby Brillantes; Christine Tam; Xiaoying Yang; Simon S Gao; Justin Q Ly; Liling Liu; Liuxi Chen; Bianca M Liederer; Joseph H Lin; Steven Magnuson; Jun Chen; David H Hackos; Justin Elstrott; Alexis Rohou; Brian S Safina; Matthew Volgraf; Rebecca N Bauer; Lorena Riol-Blanco
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

Review 10.  Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.

Authors:  Kalina R Atanasova; Leah R Reznikov
Journal:  Respir Res       Date:  2018-08-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.